Enabling leading clinical experts to solve critical problems in Duchenne drug development

Biotechnology

Collaborative Trajectory Analysis Project

Collaborative Trajectory Analysis Project's headquarters in Cambridge, MA, United States

Susan J. Ward

Craig M. McDonald

James Signorovitch

Erik Henricson

Katherine Beaverson

Gautam Sajeev

Rich Able

Yohei Sato

Ryan Fischer

Beth Bellucio

Joel Iff

Carl Morris

Brian Tseng

Naotoshi Kanemitsu

Mark Stahl

Laura Dalle Pazze

Debra Miller

Joanne Donovan

Nerissa Kreher

Gilda Shayhan

Paolo Bettica

The Advisory Team at the Collaborative Trajectory Analysis Project consists of 15 experienced advisors who provide strategic guidance and expert insights to advance drug development for Duchenne muscular dystrophy. They work collaboratively to solve critical clinical challenges and support the formulation of innovative therapeutic approaches.

Advisory Team

The Pediatric Neurology Team at Collaborative Trajectory Analysis Project focuses on leveraging their clinical expertise in pediatric neurology to advance drug development for Duchenne muscular dystrophy. The team collaborates on clinical management, rehabilitation strategies, and international research initiatives to address critical challenges and improve patient outcomes.

Pediatric Neurology Team

The Leadership Team at Collaborative Trajectory Analysis Project drives strategic direction and decision-making to advance Duchenne drug development. Comprising co-founders and seasoned executives, this team leverages their expertise to foster collaborations, align clinical goals, and ensure the successful execution of innovative solutions that address critical challenges in the field.

Leadership Team

Collaborative Trajectory Analysis Project

Org chart

Board & advisors

Teams

Advisory Team

Pediatric Neurology Team

Leadership Team

Offices

Collaborative Trajectory Analysis Project

Org chart

Board & advisors

Teams

Advisory Team

Pediatric Neurology Team

Leadership Team

Offices

Related companies